Valuation: Paradigm Biopharmaceuticals Limited

Market Cap 98.01M 68.8M 59.8M 55.66M 51.11M 96.51M 6.57B 656M 258M 3.27B 258M 253M 10.96B P/E 2026 *
-1.8x
P/E 2027 * -1.99x
Enterprise Value 64.01M 44.93M 39.06M 36.35M 33.38M 63.03M 4.29B 429M 168M 2.14B 169M 165M 7.16B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
91.43%
Yield 2026 *
-
Yield 2027 * -
1 day+3.03%
Current month+3.03%
1 month-2.86%
3 months+3.03%
6 months-46.03%
Current year-50.00%
1 week 0.16
Extreme 0.157
0.17
1 month 0.16
Extreme 0.157
0.18
Current year 0.14
Extreme 0.135
0.37
1 year 0.14
Extreme 0.135
0.47
3 years 0.14
Extreme 0.135
0.9
5 years 0.14
Extreme 0.135
2.69
10 years 0.14
Extreme 0.135
4.5
Manager TitleAgeSince
Chief Executive Officer - 2022-11-21
Director of Finance/CFO - 2023-03-02
Chief Operating Officer - -
Director TitleAgeSince
Chairman - -
Director/Board Member 60 2020-12-08
Director/Board Member - 2024-03-03
Date Insider Type Main position Quantity % Market Cap.
2/23/26 Expiration

Chief Executive Officer

50,000 0.0115%
2/23/26 Expiration

Director

354,958 0.0819%
2/23/26 Expiration

Chief Executive Officer

2,691,961 0.6210%
Change 5-day change 1-year change 3-year change Capi.($)
+3.03%0.00%-50.72%-80.90% 68.8M
-1.40%+2.59%-1.71%+12.94% 48.53B
-2.41%-0.90%+411.96%+472.09% 39.87B
-1.16%+12.96%+28.81%+7.27% 38.68B
-1.88%-3.03%+5.69%+66.52% 35.13B
-1.74%+5.12%+14.44%+44.64% 29.79B
-0.21%-4.04%+36.40%+126.06% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+14.79% 13.61B
-1.19%-1.32%-1.73%-34.97% 12.62B
Average -1.05%+0.95%+49.61%+69.83% 25.05B
Weighted average by Cap. -1.59%+2.03%+79.74%+107.43%

Financials

2026 *2027 *
Net sales - -
Net income -36.3M -25.48M -22.15M -20.62M -18.93M -35.75M -2.43B -243M -95.38M -1.21B -95.7M -93.59M -4.06B -44.8M -31.45M -27.34M -25.45M -23.36M -44.12M -3B -300M -118M -1.49B -118M -116M -5.01B
Net Debt -34M -23.87M -20.75M -19.31M -17.73M -33.48M -2.28B -228M -89.34M -1.13B -89.63M -87.66M -3.8B -12M -8.42M -7.32M -6.82M -6.26M -11.82M -804M -80.34M -31.53M -400M -31.63M -30.94M -1.34B
Logo Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. It develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. It is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.
Employees
-
Date Price Change Volume
26-08-02 A$0.1700 +3.03% 395,280
26-07-31 A$0.1650 +3.13% 873,561
26-07-30 A$0.1600 -3.03% 1,466,351
26-07-29 A$0.1650 0.00% 2,026,994
26-07-28 A$0.1650 -2.94% 613,971
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1650AUD
Average target price
1.080AUD
Spread / Average Target
+554.55%

Annual profits - Rate of surprise